LRMR
LRMR
US5171251003
Larimar Therapeutics, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±95.8% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.7x).

Beta (Market Relation)
0.69x
Defensive
Volatility (5Y p.a.)
95.8% p.a.
5-Year Horizon
Max Drawdown (5Y)
-88.6%
5-Year Horizon
Sharpe Ratio
-0.28
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -44%
3 Years 98.5% -87.1% -0.09 -6.2%
5 Years 95.8% -88.6% -0.28 -24.4%
10 Years 87.9% -98.9% -0.31 -24.5%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (95.8% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -98.9% in the extended horizon.
ende